Researchers report on the safety data from the phase 3 ASCENT trial of sacituzumab govitecan in the treatment of metastatic triple-negative breast cancer.
Besremi is a monopegylated, long-acting interferon, which exhibits its cellular effects in the bone marrow in polycythemia vera.
Adding trabectedin to doxorubicin doubled the median progression-free survival.
Race and ethnicity were reported in less than 25% of the trials studied.
The median duration of response was not reached at a median follow-up of 26 months.